
Marc P. Bonaca, MD, MPH, of the University of Colorado School of Medicine, comments on the potential to personalize treatment with emerging therapies in the pipeline to better manage patients at high risk for cardiovascular disease in the future.

Marc P. Bonaca, MD, MPH, of the University of Colorado School of Medicine, comments on the potential to personalize treatment with emerging therapies in the pipeline to better manage patients at high risk for cardiovascular disease in the future.

Unmet needs in the management of coronary artery disease and peripheral artery disease, and advice for working with patients and other healthcare professionals to optimize care for patients at high risk for cardiovascular disease.

Drs Marc P. Bonaca and Manesh R. Patel discuss the rationale for individualized treatment plans for patients with type 2 diabetes at high risk for cardiovascular disease.

Implications for treating patients at risk of cardiovascular disease with rivaroxaban plus aspirin based on the COMPASS and VOYAGER PAD clinical trials.

Recommendations for treating patients with coronary artery disease and type 2 diabetes with dual antiplatelet therapy based on data revealed by the THEMIS trial.

Strategies used to help determine patients’ risk for cardiovascular disease and the role of lifestyle management in helping reduce the risk for events in patients with type 2 diabetes.

Strategies used to help determine patients’ risk for cardiovascular disease and the role of lifestyle management in helping reduce the risk for events in patients with type 2 diabetes.

Drs Marc P. Bonaca and Manesh R. Patel discuss the link between type 2 diabetes and cardiovascular disease along with risk factors that may lead to cardiovascular events.

June 14th 2021

June 21st 2021

June 7th 2021

June 14th 2021